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Hepatitis C virus (HCV) infects the liver and hepatocytes are the major cell type supporting viral
replication. Hepatocytes and cholangiocytes derive from a common hepatic progenitor cell that
proliferates during inflammatory conditions, raising the possibility that cholangiocytes may support
HCV replication and contribute to the hepatic reservoir. We screened cholangiocytes along with a
panel of cholangiocarcinoma-derived cell lines for their ability to support HCV entry and
replication. While primary cholangiocytes were refractory to infection and lacked expression of
several entry factors, two cholangiocarcinoma lines, CC-LP-1 and Sk-ChA-1, supported efficient
HCV entry; furthermore, Sk-ChA-1 cells supported full virus replication. In vivo
cholangiocarcinomas expressed all of the essential HCV entry factors; however, cholangiocytes
adjacent to the tumour and in normal tissue showed a similar pattern of receptor expression to ex
vivo isolated cholangiocytes, lacking SR-BI expression, explaining their inability to support
infection. This study provides the first report that HCV can infect cholangiocarcinoma cells and
suggests that these heterogeneous tumours may provide a reservoir for HCV replication in vivo.
INTRODUCTION
Hepatitis C virus (HCV) is an enveloped positive strand
RNA virus classified in the genus Hepacivirus of the family
Flaviviridae. Worldwide, approximately 170 million indi-
viduals are persistently infected with HCV that leads to a
progressive liver disease, including cirrhosis and hepato-
cellular carcinoma (reviewed by Scheel & Rice, 2013). The
major cell type in the liver supporting HCV replication is
hepatocytes (Kandathil et al., 2013; Wieland et al., 2014).
Hepatocytes and cholangiocytes derive from a common
epithelial progenitor cell that proliferates during liver
inflammation (Roskams, 2006); however, to date there
are no published studies investigating the permissivity of
cholangiocytes to support HCV infection.
Cholangiocarcinomas account for approximately 10% of all
primary hepatic cancers and can be classified as intrahepatic
or extrahepatic in location (Patel, 2006; Roskams, 2006).
Cholangiocarcinomas are heterogeneous and can arise from
cholangiocytes, liver progenitor cells (Komuta et al., 2012)
or hepatocytes (Fan et al., 2012; Sekiya & Suzuki, 2012).
HCV is a known risk factor for cholangiocarcinoma,
together with hepatitis B virus and other chronic inflam-
matory conditions (Patel, 2006; Ralphs & Khan, 2013).
Primary cholangiocytes isolated from donor liver tissue,
along with a panel of cholangiocarcinoma derived cell lines,
were screened for their ability to support HCV entry and
replication. Primary cholangiocytes were refractory to HCV
entry or replication, however, two cholangiocarcinoma cell
lines supported efficient HCV entry. Furthermore one of
the tumour lines, Sk-ChA-1, supported HCV entry and
replication at comparable levels to primary human hepato-
cytes. Cholangiocarcinoma tumours expressed all of the
essential HCV entry factors, whereas biliary epithelia lacked
expression of one essential entry receptor, scavenger receptor
BI (SR-BI). In summary, we demonstrate that a subset of
cholangiocarcinomas support HCV replication, consistent
with reports showing HCV RNA in intrahepatic cholangio-
carcinomas (Lu et al., 2000; Perumal et al., 2006; Yin &
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Chen, 1998), highlighting a potential new reservoir that
merits further investigation.
RESULTS
Cholangiocarcinomas support HCV pseudotype
particle (HCVpp) entry
To investigate the ability of cholangiocytes to support HCV
entry we screened primary cells isolated from 10 donor
liver explants with various disease aetiologies, together with
cell lines derived from normal tissue (H69), intra- (CC-LP-
1 and CC-SW-1) and extra-hepatic cholangiocarcinomas
(Sk-ChA-1 and Mz-ChA-1). We confirmed that all of the
cholangiocarcinoma derived lines expressed the epithelial
markers EpCAM, CK19 and epithelial membrane antigen
NCAM and GCTM-5. HCVpp failed to infect any of the
primary cholangiocytes, however, we observed efficient
entry into two cell lines, CC-LP-1 and Sk-ChA-1 (Fig. 1a).
All cell lines tested supported vesicular stomatitis virus G
pseudotype particle (VSV-Gpp) entry, demonstrating
functional lentiviral promoter activity in these cells (Fig.
1a). To investigate whether cholangiocarcinoma cells
supported the entry of HCVpp expressing diverse envelope
glycoproteins, we generated pseudoparticles expressing E1E2
glycoproteins cloned from HCV genotype 1a/b acutely
infected subjects (Osburn et al., 2014). As controls we
included the well-characterized Huh-7 hepatoma line and
the non-permissive claudin-1 null human embryonic kidney
293T cell line. All HCVpp strains infected CC-LP-1 and Sk-
ChA-1 cholangiocarcinoma lines with comparable efficiency
to Huh-7 but failed to infect 293T (Fig. 1b). We confirmed
that CC-SW-1 and Mz-ChA-1 cells were refractory to all
patient-derived HCVpp (data not shown). To investigate the
receptor dependency of HCVpp infection of the permissive
cholangiocarcinoma lines, we assessed the ability of anti-
CD81 and anti-SR-BI antibodies to inhibit HCVpp (strain
H77) infection. Both antibodies inhibited HCVpp entry,
demonstrating receptor-dependent entry (Fig. 1c). In addi-
tion, anti-E2 (3/11) and polyclonal IgG purified from chronic-
HCV infected subjects inhibited HCVpp infectivity (Fig. 1c)
but had no effect on VSV-Gpp infection (data not shown).
These studies show that some tumour-derived cholangio-
cytes but not those isolated from non-tumour liver tissue
support HCVpp entry.
Cholangiocarcinoma express HCV entry factors
To investigate HCV entry factor expression in vivo we
stained cholangiocarcinoma liver tissue from two donors
with antibodies specific for CD81, SR-BI, claudin-1,
occludin and epithelial marker CK19. Cholangiocarcinoma
from both donors expressed all four HCV entry factors,
albeit with low CD81 expression (Fig. 2a), whereas biliary
epithelia from the normal non-tumour margin lacked SR-BI
expression (Fig. 2b). To assess whether the cholangiocarcin-
oma cell lines show a similar profile of receptor expression to
the tumour tissue, the cells were stained for receptor
expression along with Huh-7 hepatoma cells as a positive
control. The permissive cell line Sk-ChA-1 expressed all four
entry factors at comparable levels to Huh-7 hepatoma cells
(Fig. 3a). Of note, CC-LP-1 cells expressed CD81, SR-BI and
occludin; however, we failed to detect any claudin-1
expression (Fig. 3a). Both permissive cell lines expressed
CD81 and occludin at the plasma membrane; however,
claudin-1 was predominantly intracellular in Sk-ChA-1 cells
and not observed in CC-LP-1 cells (Fig. 3b). The two non-
permissive cholangiocarcinoma lines, CC-SW-1 and Mz-
ChA-1, expressed low levels of SR-BI, similar to that
observed for biliary epithelia in non-tumour liver tissue,
suggesting that this may be the limiting factor for HCV
entry. These data show that cholangiocarcinoma and
epithelial cells isolated from the tumour express all four
HCV entry receptors, consistent with their permissivity to
support HCV entry.
Cholangiocarcinoma CC-LP-1 express negligible
claudin-1, -6 and -9 and yet support HCV entry
Several studies have reported that HCV can use several
members of the claudin family to infect cells, including
claudin-1, -6 and -9 (Meertens et al., 2008; Zheng et al.,
2007). Western blot analysis for claudin-1 expression
confirmed our earlier confocal images and flow cytometry
data that claudin-1 was undetectable in CC-LP-1 cells (Fig.
3c). Furthermore, we failed to detect claudin-1, -6 and -9
mRNA in CC-LP-1 cells (Fig. 3d). As expected, Huh-7
expressed high levels of claudin-1 and -6 mRNA but
minimal claudin-9, consistent with previous reports
(Zheng et al., 2007).
To determine whether HCVpp expressing patient-derived
envelope glycoproteins required claudin-1 to initiate
infection we assessed their ability to infect the claudin-
null cell line, 293T, and CC-LP-1 cells following claudin-1
overexpression. Claudin-1 expression was confirmed by
flow cytometry (data not shown). HCVpp strains only
infected 293T cells expressing claudin-1, demonstrating
claudin-1 dependent entry. However, the same viruses
infected parental CC-LP-1 cells, however, their infection
levels were increased following claudin-1 expression in this
cellular background (Fig. 4). In summary, diverse HCVpp
strains infect CC-LP-1 cholangiocarcinoma cells independ-
ent of claudin-1, -6 or -9 expression.
Cholangiocarcinoma Sk-ChA-1 support HCV entry
and genome replication
Sk-ChA-1 cells support cell-culture-derived HCV (HCVcc)
(strains SA13/JFH-1 and JFH-1) replication as assessed by
enumerating NS5A expressing cells, whereas CC-LP-1 failed
to express detectable levels of viral antigen or RNA. Similar
results were obtained with CC-LP-1 cells transduced to
express claudin-1, suggesting that their non-permissivity to
support HCVcc replication was not due to a claudin-1
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independent viral uptake pathway. Foci of NS5A expressing
Sk-ChA-1 only comprised on average 2–4 cells, suggesting
minimal viral spread. Infection was inhibited by polyclonal
patient IgG from pooled HCV-infected donors, neutralizing
anti-CD81, Telaprevir (VX-950) and interferon-a (Fig. 5a).
To compare the permissivity of Sk-ChA-1 cells to support
HCV replication to primary human hepatocytes (PHHs) we
measured HCV RNA levels 72 h post-infection and included
permissive Huh-7 cells as a positive control. We noted
comparable levels of HCV RNA in Sk-ChA-1 and PHHs
from two donors (Fig. 5b). Huh-7 cells supported
significantly higher levels of HCV replication, most likely
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Fig. 1. HCVpp infects cholangiocarcinoma cell lines. (a) Primary cholangiocytes or cholangiocarcinoma cell lines, along with
control permissive (Huh-7 hepatoma) and non-permissive (293T) cells, were infected with HCVpp (strain H77) or VSV-Gpp,
and infection levels expressed relative to the no-envelope control. (b) Infectivity of HCVpp expressing primary envelope
glycoproteins (Osburn et al., 2014) for CC-LP-1 and Sk-ChA-1 along with Huh-7 and 293T control cells. (c) Anti-receptor
antibodies (anti-CD81 or SR-BI), anti-HCV Ig or anti-E2 (3/11) inhibition of HCVpp infection of CC-LP-1, Sk-ChA-1
and control Huh-7 cells. Data are presented relative to control antibody. N53 independent experiments. ****P,0.0001,
***P,0.001, **P,0.01, *P,0.05.
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explained by their negligible Toll-like receptor 3 (TLR3)
expression and limited ability to sense replicating RNA
(Wang et al., 2009). Attempts to infect the highly permissive
Huh-7.5 cell line with extracellular virus secreted from Sk-
ChA-1 or PHHs cells failed to establish infection, most likely
due to the low frequency of infected cells and comparable to
the life cycle observed in infected neuroepithelioma cells
(Fletcher et al., 2010).
Several cellular factors have been demonstrated to facilitate
HCV infection and replication, including miR-122 (Jopling
et al., 2005), Niemann-Pick C1-like 1 (NPC1L1) cholesterol
absorption receptor (Sainz et al., 2012) and Apolipoprotein
E (ApoE) (Jiang & Luo, 2009). We therefore investigated the
expression of these factors in the two cholangiocarcinoma
cell lines. Neither CC-LP-1 nor Sk-ChA-1 cells expressed
detectable levels of miR-122 (Fig. 5c). Both cell lines expressed
NPC1L1 at similar levels to Huh-7 cells, as measured by
Western blotting (data not shown), suggesting that neither
of these reported host-cell factors explained the differential
permissivity of the cholangiocarcinoma cells to support
HCVcc infection. In contrast, we noted a significant dif-
ference in ApoE expression between the two lines, with the
permissive Sk-ChA-1 secreting detectable levels of ApoE
(Fig. 5d). These results demonstrate that Sk-ChA-1, but not
CC-LP-1, cholangiocarcinoma cells support HCV replication.
DISCUSSION
CC-LP-1 and Sk-ChA-1 cells derived from intra- and extra-
hepatic cholangiocarcinoma tissue, respectively, support
HCV entry or replication. In contrast, HCV did not infect
primary cholangiocytes. Infection of cholangiocarcoma
cells was inhibited by antibodies specific for CD81, SR-BI,
E2 glycoprotein and by pooled immunoglobulin from
chronic HCV infected patients. Of note, CC-LP-1 expressed
negligible levels of tight junction protein, claudin-1 mRNA
or protein and yet supported the entry of HCVpp expressing
a range of patient-derived envelope glycoproteins. CCl-LP-1
cells do not express detectable levels of claudin-6 or -9
mRNA suggesting that infection is claudin-independent. We
confirmed that the infectivity of all HCVpp strains tested
were claudin-1 dependent in 293T cells and expression of
claudin-1 in CC-LP-1 cells significantly enhanced HCVpp
entry. To the best of our knowledge this is the first report of
claudin-1 independent HCV entry into hepatic derived
epithelial cells and supports a model where CD81 and SR-BI
mediate viral attachment and internalization in the absence
of claudin-1, -6 or -9 co-expression.
Cholangiocytes and hepatocytes arise from a common
progenitor cell type, termed oval cells in rodents and
reactive ductular cells in humans (Roskams, 2006). During
chronic liver diseases, reactive ductular cells become activated
and differentiate into cholangiocytes and hepatocytes, de-
pending on the nature of the liver injury. Cholangio-
carcinomas develop from cholangiocytes and reactive
ductular cells, however, recent studies provide evidence that
intrahepatic cholangiocarcinoma can also originate from
hepatocytes (Fan et al., 2012; Sekiya & Suzuki, 2012). This
occurs through activation of NOTCH and AKT signalling in
hepatocytes, leading to the conversion of hepatocytes into
cholangiocytes with concurrent malignant transformation
(Fan et al., 2012). These data may explain why viral hepatitis
is a risk factor for cholangiocarcinoma, since infected
hepatocytes can undergo NOTCH activation and lineage
conversion (Iwai et al., 2011; Sekiya & Suzuki, 2012).
We did not assess the ability of purified hepatic progenitor
cells to support HCV infection, however, NCAM and
EpCAM-positive cholangiocytes isolated from donor livers
with primary biliary cirrhosis are known to contain an
enriched population of reactive ductular cells, and were
refractory to infection. In addition, primary cholangiocytes
isolated from subjects with primary sclerosing cholangitis,
a condition that predisposes to cholangiocarcinoma, were
refractory to infection (Roskams et al., 1990) (E. Gershwin,
personal communication). CC-LP-1 and CC-SW-1 cells are
derived from intrahepatic cholangiocarcinomas (Shimizu
et al., 2006) whereas Sk-ChA-1 and Mz-ChA-1 are derived
from extrahepatic tumours of the biliary tree and gall
bladder, respectively (Knuth et al., 1985), indicating that
the ability to support HCV replication is not restricted to
intrahepatic cholangiocarcinomas.
Viral tropism is defined at multiple levels of the virus life
cycle, including entry, RNA replication and assembly
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Fig. 2. Cholangiocarcinoma expresses HCV entry factors. (a)
Cholangiocarcinoma and (b) normal non-tumour margin tissue was
stained (arrows) with antibodies specific for HCV receptors
(CD81, SR-BI, claudin-1 and occludin) (green) and epithelial
marker CK19 (red). A representative donor tissue is shown, where
arrows denote dual CK19/receptor expressing cells. Scale bars
represent 20 mm.
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(reviewed by Scheel & Rice, 2013). In addition to the four
essential factors for HCV entry, CD81, SR-BI, claudin-1
and occludin, several additional factors facilitate infection.
These include epidermal growth factor receptor (EGFR)
(Lupberger et al., 2011), Niemann-Pick C1-like 1 choles-
terol absorption receptor (Sainz et al., 2012) and the liver-
specific micro-RNA, miR-122 (Jopling et al., 2005). Virus
particles are secreted in association with apolipoproteins
and ApoE expression enhances viral infectivity and virus
particle production (Da Costa et al., 2012; Hueging et al.,
2013; Jiang & Luo, 2009). Sk-ChA-1, but not CC-LP-1,
cells supported HCV replication that was inhibited by
interferon-a, anti-CD81, HCV-positive pooled patient IgG
and Telaprevir. While the levels of infection observed in
Sk-ChA-1 cells was significantly lower than Huh-7 cells,
Sk-ChA-1 cells supported similar levels of infection to
PHHs. Huh-7 cells have previously been shown to support
significantly higher HCV replication than PHH, likely due
to reduced sensing of HCV RNA and a lack of TLR3
expression in these cells (Farquhar & McKeating, 2008;
Wang et al., 2009). Since Sk-ChA-1 but not CC-LP-1 cells
support HCV replication, we quantified the expression of
additional host factors reported to facilitate infection to
explore the differences in these cell lines to replicate
HCVcc. None of the cell lines expressed miR-122, similar
to our previous observations with blood–brain barrier
endothelial cells and HepG2-CD81 hepatoma cells that
support low level HCVcc replication (Fletcher et al., 2012;
Israelow et al., 2014). Of note, only Sk-ChA-1 cells secrete
detectable levels of ApoE, which, together with their
expression of the essential HCV entry factors, may explain
their permissivity to support HCV replication.
In summary, we have identified two cell lines derived from
cholangiocarcinoma tissue that support efficient HCV
entry and low-level HCV replication. Our data raises the
possibility that cholangiocarcinomas may represent a
reservoir for HCV infection in vivo and warrant further
studies to establish the role of HCV in cholangiocarcinoma
pathogenesis.
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METHODS
Cells and reagents.Huh-7 and 293T HEK cells were provided by C.
Rice (Rockefeller University) and cholangiocarcinomas (CC-LP-1,
CC-SW-1, Mz-ChA-1 and Sk-ChA-1) by P. Bosma (University of
Amsterdam). Cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% FBS, 1% non-essential
amino acids and 1% penicillin/streptomycin. H69 cells derived from
normal intrahepatic biliary epithelia were cultured as previously
reported (Grubman et al., 1994). Human hepatocytes were isolated
according to previously published protocols (Mitry, 2009) and
maintained in Williams E medium with 10% FBS/5 mM HEPES/
insulin/dexamethasone. Primary cholangiocytes were isolated from end
stage liver disease tissue and ethical permission was granted by the local
research ethics committee (CA/5192; Research Ref. 06/Q702/61).
Briefly, liver (~30 g) was diced and incubated with collagenase type
1A (Sigma). The digest was layered onto a 33% and 77% Percoll
gradient and centrifuged at 500 g for 30 min. The interface layer was
collected, washed three times in PBS, and incubated with a
cholangiocyte-specific mAb specific for HEA 125 (Progen).
Cholangiocytes were positively selected by incubating with anti-mouse
IgG1-coated Dynabeads (Invitrogen) and by magnetic separation. The
cells were cultured in DMEM, Hams F12, 10% heat-inactivated human
serum, 1% penicillin/streptomycin and glutamine, HGF (10 ng ml21,
Peprotech), EGF (10 ng ml21, Peprotech), cholera toxin (10 ng ml21,
Sigma), tri-iodo-thyronine (2 nM, Sigma), hydrocortisone (2 mg
ml21) and insulin (0.124 IU ml21). In all experiments, cells were used
between passage two and five to ensure phenotypic stability.
The following primary antibodies were used: anti-CD81 (clone 2s131);
(in house); anti-SRBI (gift from Pfizer); anti-claudin-1 (R&D
Technologies); anti-occludin (Invitrogen); anti-NS5A-9E10 (C. Rice,
Rockefeller University, NY); and anti-CK19 (Vector Laboratories).
Secondary antibodies used were: Alexa 488 goat anti-rabbit immu-
noglobulin IgG; Alexa 488 goat anti-mouse IgG; and Alexa 594 goat
anti-mouse IgG (Invitrogen).
Liver tissue and confocal imaging. Formalin fixed and paraffin
embedded biopsies were obtained from patients with cholangiocarcin-
oma that was diagnosed according to standard biochemical and
histological criteria: all tissues studied were selected by an experienced
histopathologist. Liver sections (10 mm) were deparaffinized and
rehydrated in water followed by low temperature antigen retrieval.
Sections were blocked with 2% Caesin (Vector Laboratories) and
incubated with anti-CD81, anti-SR-BI, anti-claudin-1 and anti-
occludin along with anti-CK19. Bound antibodies were detected with
Alexa-conjugated secondary anti-species antibodies and labelled
sections mounted using Fluorescent Imaging Media (Dako). Images
were acquired using an upright Zeiss 780 laser scanning confocal
microscope (10061.4NA objective), where microscope settings were
optimized for each fluorescent protein to obtain the highest signal to
noise ratio whilst controlling for cross talk. Background fluorescence
intensities were determined from the fluorescent signal of an Ig isotype
control.
Flow cytometry. Cell surface receptor expression was monitored by
live-cell staining and flow cytometry as previously reported (Fletcher
et al., 2012). Briefly, cells were incubated with anti-SR-BI, anti-CD81 or
anti-claudin-1 for 1 h. To detect occludin cells were fixed and
permeabilized followed by incubation with a primary antibody. After a
brief wash the cells were labelled with a fluorescent conjugated secondary
antibody for 1 h. Thereafter, cells were fixed with 1% paraformaldehye
(Sigma) and data collected using a FACS calibur flow cytometer (BD
Biosciences) and analysed with FlowJo software (Tree Star).
HCVpp and HCVcc genesis and infection. Pseudoparticles were
generated by transfecting 293T cells with plasmids encoding a human
immunodeficiency virus (HIV) provirus expressing luciferase and
vesicular stomatitis virus G (VSV-G), a panel of HCV envelope
glycoproteins (Dowd et al., 2009) or a no-envelope control, as
previously reported (Hsu et al., 2003). Supernatants were harvested at
48 h post-transfection, clarified and filtered through a 0.45 mm
membrane. Virus-containing medium was added to target cells plated
in 96-well plates seeded at 56105 cells cm22. At 72 h post-infection,
cells were lysed and luciferase activity measured in a luminometer
(Lumat LB 9507). HCVpp infectivity was calculated by expressing the
HCV or VSV-G luciferase signal (relative light units, RLU) relative to
the No env RLU value. HCVcc NS5A-positive foci were enumerated
and infectivity expressed as f.f.u. ml21.
To generate HCVcc, plasmids encoding chimeric SA13/JFH (Jensen
et al., 2008) or J6/JFH-1 (Lindenbach et al., 2005) were used to generate
HCV RNA as previously described (Lindenbach et al., 2005). Briefly,
RNA was electroporated into Huh-7.5 cells, supernatants collected at
72 and 96 h and stored at 280 uC. Various cell lines and PHHs were
inoculated with HCVcc for 6 h in the presence or absence of anti-HCV
Ig (100 mg ml21), anti-CD81 (2s131 at 10 mg ml21), Telapravir (1 mg
ml21) or interferon-a (10 IU ml21). Unbound virus was removed by
washing and the cells re-fed fresh media plus or minus antiviral agents
and propagated for 72 h before fixing for NS5A detection or extraction
of total cellular RNA for HCV RNA quantification. Cells were fixed
with ice-cold methanol and stained for NS5A with mAb 9E10 and an
isotype-matched Alexa 488-conjugated anti-mouse IgG2a.
Neutralization of HCV infection. Huh-7, CC-LP-1, Sk-ChA-1 or
293T cells were seeded in 96-well plates at 56105 cells cm22. The cells
were incubated 24 h post-seeding with 10 mg ml21 anti-receptor or
irrelevant IgG control mAb. After 1 h, HCV-H77pp, VSV-Gpp or
No-envpp, or HCVcc, was added and incubated for 72 h at 37 uC. In
addition, anti-E2 mAbs or HCV+ IgG was incubated with virus for
1 h prior to infecting the appropriate target cells. At 72 h post-
infection, luciferase activity was measured for HCVpp infections, or
cells stained for NS5A. The percentage neutralization was calculated
relative to the irrelevant IgG control.
Transduction of cells to express claudin-1. CC-LP-1 or 293T cells
were transduced to express claudin-1 as previously described (Flint
et al., 2006; Harris et al., 2010). Briefly, packaged lentiviruses to
express claudin-1 were generated by cotransfection of 293T cells with
plasmids encoding VSV-G protein, HIV Gag-Pol, and pTRIP-
claudin-1 (1 : 3:3 ratio). Cells were seeded at 46105 cells cm22 and
infected 24 h later with the packaged lentivirus. After 12 h, cells were
seeded into appropriate plates either for HCVpp or HCVcc infection
as described.
Real-time reverse transcriptase PCR. RNA was prepared using the
Qiagen RNeasy or MiRNeasy kit for microRNA analysis. Purified
cellular RNA samples were amplified for HCV RNA (Primer Design
Ltd), claudin-1, -6 or -9, or miR-122 in a quantitative reverse-
transcription PCR (qRT-PCR) in accordance with the manufacturer’s
guidelines (CellsDirect kit; Invitrogen) using an ABI7500 PCR
machine (Applied Biosystems). Glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) or miR-210 were included as endogenous
controls for amplification efficiency, and HCV amplification normal-
ized to GAPDH using the DDCt method.
ApoE ELISA. Cells were cultured for 24 h and supernatant harvested.
Secreted ApoE levels were measured using a commercial ApoE ELISA
(Abcam) according to the manufacturer’s instructions.
Statistical analysis. Results are expressed as the mean±1 standard
deviation of the mean. Statistical analyses were performed using
Student’s t-test in Prism 6.0 (GraphPad) with a P,0.05 being
considered statistically significant.
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